Drug
Zirconium-89 clinical trials
- studies test it
- 10
- open now
- 6
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the Zirconium-89 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStudies by the year they started
10 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 6
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Boehringer Ingelheim (3) · University of Alabama at Birmingham (3) · Citryll BV (1) · Robert Flavell, MD, PhD (1) · Nerissa T. Viola (1) · Aplagon Oy (1)
Often tested with
Tested in the same studies.
Anti-SIRPa Monoclonal Antibody BI 765063 (1) · Anti-SIRPa Monoclonal Antibody BI 770371 (1) · Obrixtamig (1) · Miptenalimab (1) · Ezabenlimab (1)
Studies
Open first, then newest update. How each study uses Zirconium-89 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerRecruitingPhase 1Boehringer IngelheimNCT05963867Written as [89Zr]Zr-BI 764532
- Imaging Study of [89Zr]DFO-YS5 for Cancer DetectionRecruitingPhase 1Robert Flavell, MD, PhDNCT07664397Written as [89Zr]DFO-YS5
- First-in-human Study of Interferon-y PET Imaging to Assess Response to ImmunotherapyRecruitingPhase 1Nerissa T. ViolaNCT06439914Written as [89Zr]Zr-DFO-emapalumab
- Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy EffectivenessRecruitingEarly Phase 1University of Alabama at BirminghamNCT03321045Written as [89Zr]-Df-Trastuzumab
- Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell CarcinomaRecruitingEarly Phase 1University of Alabama at BirminghamNCT05183048Written as [89Zr]Panitumumab Tracer
- Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)RecruitingEarly Phase 1Aplagon OyNCT06204237Written as [89Zr]Zr-DFO-APAC
- PET-Based Imaging of Radiolabeled CIT-013CompletedPhase 2Citryll BVNCT07147959Written as [89Zr]Zr-CIT
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingPhase 1Boehringer IngelheimNCT05068102Written as [89Zr]Zr- BI 765063
- This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedPhase 1Boehringer IngelheimNCT03780725Written as [89Zr]Zr-BI 754111
- Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal CancerWithdrawnPhase 1/2University of Alabama at BirminghamNCT03764137Written as [89Zr]Panitumumab PET-MRI
Given in every arm · 2 — Zirconium-89 is usual care beside what is tested
- Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTorNot yet recruitingPhase 2/3Radboud University Medical CenterNCT06218069Written as [89Zr]Zr-crefmirlimab berdoxam
- A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy AdultsCompletedPhase 1BiogenNCT06454721Written as [89Zr]Zr-DFO-Diranersen
Codes
What other systems call Zirconium-89 · ClinicalTrials.gg INT000641
- MeSH (NLM) C000615502Zirconium-89One source NLM
- UNII (FDA) NTM296JU95ZIRCONIUM ZR-89Confirmed NLM, Wikidata
- Wikidata Q18845332zirconium-89Confirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615502 | Zirconium-89 | One source NLM |
| UNII (FDA) | NTM296JU95 | ZIRCONIUM ZR-89 | Confirmed NLM, Wikidata |
| Wikidata | Q18845332 | zirconium-89 | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.